Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection

Manuel A. Giraldo, Gabriela Arevalo-Pinzon, Jose Rojas-Caraballo, Alvaro Mongui, Raul Rodriguez, Manuel A. Patarroyo

Resultado de la investigación: Contribución a RevistaArtículo

12 Citas (Scopus)

Resumen

Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge. © 2009 Elsevier Ltd. All rights reserved.
Idioma originalEnglish (US)
Páginas (desde-hasta)7-13
Número de páginas7
PublicaciónVaccine
DOI
EstadoPublished - dic 10 2009

Huella dactilar

Plasmodium vivax
Merozoites
merozoites
surface proteins
adjuvants
Aotus (Cebidae)
Membrane Proteins
Vaccination
vaccination
immune response
Haplorhini
monkeys
Schizonts
Aluminum Hydroxide
schizonts
aluminum hydroxide
burden of disease
Freund's Adjuvant
Cost Control
vaccine development

Citar esto

Giraldo, Manuel A. ; Arevalo-Pinzon, Gabriela ; Rojas-Caraballo, Jose ; Mongui, Alvaro ; Rodriguez, Raul ; Patarroyo, Manuel A. / Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection. En: Vaccine. 2009 ; pp. 7-13.
@article{2de38a6e4d8e4c868bfea530023e4f37,
title = "Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection",
abstract = "Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge. {\circledC} 2009 Elsevier Ltd. All rights reserved.",
author = "Giraldo, {Manuel A.} and Gabriela Arevalo-Pinzon and Jose Rojas-Caraballo and Alvaro Mongui and Raul Rodriguez and Patarroyo, {Manuel A.}",
year = "2009",
month = "12",
day = "10",
doi = "10.1016/j.vaccine.2009.09.046",
language = "English (US)",
pages = "7--13",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection. / Giraldo, Manuel A.; Arevalo-Pinzon, Gabriela; Rojas-Caraballo, Jose; Mongui, Alvaro; Rodriguez, Raul; Patarroyo, Manuel A.

En: Vaccine, 10.12.2009, p. 7-13.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection

AU - Giraldo, Manuel A.

AU - Arevalo-Pinzon, Gabriela

AU - Rojas-Caraballo, Jose

AU - Mongui, Alvaro

AU - Rodriguez, Raul

AU - Patarroyo, Manuel A.

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge. © 2009 Elsevier Ltd. All rights reserved.

AB - Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge. © 2009 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2009.09.046

DO - 10.1016/j.vaccine.2009.09.046

M3 - Article

SP - 7

EP - 13

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -